How is detemir different from NPH insulin?

Detemir binds albumin to release more slowly and predictably, and in trials it caused less nocturnal hypoglycaemia and less weight gain than NPH, though both still lower glucose effectively.

Can I adjust my own detemir dose?

No. Insulin dosing is titrated by your prescriber to your glucose readings, diet, activity and health status; changing it yourself can cause dangerous highs or lows.

Is Levemir still available?

Detemir remains an approved product, but its manufacturer announced a phased withdrawal of Levemir in the United States, so availability differs by country - check with your pharmacist or clinician.

EMA-approvedaka Levemir

Insulin detemir — Complete Research Guide (2026)

Q: What is the main risk of insulin detemir?

Hypoglycaemia (low blood sugar), which can become severe; other effects include injection-site reactions, lipodystrophy and, rarely, low potassium. Dosing must be individualized.

Last updated 2026-06-30

TL;DR

Insulin detemir (also known as Levemir) is a peptide catalogued under Hormones & Metabolic (Long-acting insulin analogue). It is described as: Insulin receptor agonist. Documented context: Diabetes mellitus. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Insulin detemir?

Insulin detemir (brand name Levemir) is a long-acting basal insulin analog in which a fatty-acid (myristic acid) side chain lets it bind reversibly to albumin, prolonging and smoothing its action. It is a prescription injectable approved by the FDA (2005) and EMA (2004) for glycaemic control in adults and children with type 1 and type 2 diabetes.

Evidence is strong and human: multiple randomized treat-to-target trials and Cochrane systematic reviews support its use. Note that its manufacturer announced a phased discontinuation of Levemir in the United States, so availability varies by region.

How does Insulin detemir work?

Detemir is a human insulin analog acylated with a C14 fatty acid that binds albumin at the injection site and in circulation, creating a depot that releases insulin slowly and gives a flatter, more reproducible basal profile than NPH.

Like all insulins it activates the insulin receptor, promoting glucose uptake and suppressing hepatic glucose output.

What does the research say about Insulin detemir?

In insulin-naive type 2 diabetes, adding once- or twice-daily detemir to oral agents achieved target glycaemic control with significantly less weight gain than NPH insulin. ^[1]
In type 1 diabetes on a basal-bolus regimen, detemir produced more predictable glucose control and a lower risk of hypoglycaemia than NPH. ^[2]
Over 12 months in type 1 diabetes, detemir was associated with lower nocturnal hypoglycaemia risk and less weight gain than NPH. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes — Hermansen K et al., Diabetes Care 2006. (Randomized controlled trial)
[2] Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart — Vague P et al., Diabetes Care 2003. (Randomized controlled trial)
[3] Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin — De Leeuw I et al., Diabetes, Obesity and Metabolism 2005. (Randomized controlled trial)
[4] Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes — Philis-Tsimikas A et al., Clinical Therapeutics 2006. (Randomized controlled trial)
[5] (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus — Semlitsch T et al., Cochrane Database of Systematic Reviews 2020. (Systematic review / meta-analysis)
[6] Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus — Horvath K et al., Cochrane Database of Systematic Reviews 2007. (Systematic review / meta-analysis)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

Detemir is given by subcutaneous injection once or twice daily as the basal component of a diabetes regimen; the amount is titrated to fasting glucose targets under medical supervision. This encyclopedia does not provide dosing instructions - regimens must be set and adjusted by the treating clinician.

It should never be given intravenously or in an insulin pump, and it must not be interchanged unit-for-unit with other insulins without professional guidance.

Side effects & safety profile

Hypoglycaemia is the main and potentially severe risk of all insulins, including detemir; symptoms range from tremor and sweating to confusion, seizure or loss of consciousness and require prompt treatment. Compared with NPH, trials show detemir tends to cause less hypoglycaemia (especially nocturnal) and less weight gain, but it does not eliminate these risks.

Other adverse effects include injection-site reactions, lipodystrophy with poor site rotation, and hypokalaemia.

Dosing must be individualized by a clinician and adjusted for renal or hepatic function, illness, diet and activity.

Stacking & combinations

In practice detemir is used as the basal insulin within a basal-bolus regimen alongside a rapid-acting mealtime insulin, always under clinical supervision - not as a self-directed stack.

Finding Insulin detemir vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is a long-acting basal insulin approved to help control blood glucose in adults and children with type 1 or type 2 diabetes, usually as the background insulin in a broader regimen set by a clinician.

References

[1] A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes — Hermansen K et al., Diabetes Care 2006. PMID: 16732007. View sourceStudy: Randomized controlled trialDetemir added to oral agents matched NPH for glycaemic control with significantly less weight gain and less hypoglycaemia.
[2] Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart — Vague P et al., Diabetes Care 2003. PMID: 12610006. View sourceStudy: Randomized controlled trialDetemir gave more predictable fasting glucose and lower hypoglycaemia risk than NPH in type 1 diabetes.
[3] Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin — De Leeuw I et al., Diabetes, Obesity and Metabolism 2005. PMID: 15642078. View sourceStudy: Randomized controlled trialOver 12 months detemir reduced nocturnal hypoglycaemia and weight gain versus NPH in type 1 diabetes.
[4] Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes — Philis-Tsimikas A et al., Clinical Therapeutics 2006. PMID: 17157113. View sourceStudy: Randomized controlled trialOnce-daily detemir improved control comparably to NPH with less hypoglycaemia and weight gain in type 2 diabetes.
[5] (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus — Semlitsch T et al., Cochrane Database of Systematic Reviews 2020. PMID: 33166419. View sourceStudy: Systematic review / meta-analysisLong-acting analogues including detemir modestly reduced symptomatic and nocturnal hypoglycaemia versus NPH, with similar HbA1c.
[6] Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus — Horvath K et al., Cochrane Database of Systematic Reviews 2007. PMID: 17443605. View sourceStudy: Systematic review / meta-analysisDetemir and glargine offered little HbA1c advantage over NPH but reduced hypoglycaemia and, for detemir, weight gain.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.